Literature DB >> 19497632

Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients.

Masami Ishiyama1, Eiji Suzuki, Jun Katsuda, Hiroshi Murase, Yoshitaka Tajima, Yukio Horikawa, Shinobu Goto, Tamio Fujita, Jun Takeda.   

Abstract

Vascular calcification is frequently accompanied by intima-media thickening, but the associations among these atherosclerotic features and bone-related peptides in diabetic patients are unclear. We enrolled 168 type 2 diabetic patients and 40 non-diabetic subjects consecutively admitted to our hospital. Mean intima-media thickness (mean-IMT) in common carotid arteries was measured by B-mode ultrasonography. Agatston coronary artery calcium score (CACS) was obtained using multidetector-row computed tomography (MDCT). Plasma bone-related peptides osteopontin and osteoprotegerin levels were measured. Diabetic patients had higher mean-IMT (p=0.0002) and log(CACS+1) (p<0.0001) and similar bone-related peptides compared to non-diabetic subjects. In diabetic patients classified into tertiles according to their CACS levels, those with the highest scores showed the highest mean-IMT (p=0.0004) and bone-related peptides (p<0.05) among the groups. log(CACS+1) and mean-IMT were associated (p<0.0001) and were positively correlated with osteopontin (p<0.01) and osteoprotegerin (p<0.01) in diabetic patients. Multivariate analyses revealed that the significant independent determinants of log(CACS+1) were age, duration of diabetes and osteopontin (p<0.0001) and those of mean-IMT were age, hypertension, osteopontin and osteoprotegerin (p<0.0001), respectively. We have demonstrated that vascular calcification in type 2 diabetic patients is frequently accompanied by intima-media thickening, and osteopontin may act as a vascular calcification inhibitor by increasing intima-media thickness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497632     DOI: 10.1016/j.diabres.2009.04.023

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  14 in total

1.  Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis.

Authors:  Hala Abdel-Hameed Abdel-Azeez; Manar Al-Zaky
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.

Authors:  Muyesser Sayki Arslan; Esra Tutal; Mustafa Sahin; Melia Karakose; Bekir Ucan; Gulfer Ozturk; Erman Cakal; Zeynep Biyikli Gencturk; Mustafa Ozbek; Tuncay Delibasi
Journal:  Endocrine       Date:  2016-10-15       Impact factor: 3.633

3.  Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?

Authors:  P Rozas Moreno; R Reyes García; A García-Martín; M Varsavsky; J A García-Salcedo; M Muñoz-Torres
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

4.  Vascular smooth muscle cell differentiation to an osteogenic phenotype involves matrix metalloproteinase-2 modulation by homocysteine.

Authors:  Tingjiao Liu; Jinghan Lin; Ting Ju; Lei Chu; Liming Zhang
Journal:  Mol Cell Biochem       Date:  2015-05-19       Impact factor: 3.396

5.  Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case-control study (The OSMOSIS Study).

Authors:  Julie Contenti; Matthieu Durand; Sandor Vido; Serge Declemy; Juliette Raffort; Joseph Carboni; Sophie Bonnet; Christophe Koelsch; Réda Hassen-Khodja; Philippe Gual; Nathalie M Mazure; Nirvana Sadaghianloo
Journal:  J Nephrol       Date:  2021-09-01       Impact factor: 3.902

6.  Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.

Authors:  Mikael K Poulsen; Mads Nybo; Jordi Dahl; Susanne Hosbond; Tina S Poulsen; Allan Johansen; Poul F Høilund-Carlsen; Henning Beck-Nielsen; Lars M Rasmussen; Jan E Henriksen
Journal:  Cardiovasc Diabetol       Date:  2011-08-12       Impact factor: 9.951

Review 7.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

8.  Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma.

Authors:  Catherine L Higgins; Salim Isbilir; Pamela Basto; Iou Yih Chen; Muthiah Vaduganathan; Periyanan Vaduganathan; Michael J Reardon; Gerald Lawrie; Leif Peterson; Joel D Morrisett
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

9.  Osteoprotegerin as a marker of atherosclerosis in diabetic patients.

Authors:  Areti Augoulea; Nikolaos Vrachnis; Irene Lambrinoudaki; Konstantinos Dafopoulos; Zoe Iliodromiti; Angelos Daniilidis; Michail Varras; Andreas Alexandrou; Efthymios Deligeoroglou; George Creatsas
Journal:  Int J Endocrinol       Date:  2013-01-17       Impact factor: 3.257

10.  Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells.

Authors:  Loïc Louvet; Janine Büchel; Sonja Steppan; Jutta Passlick-Deetjen; Ziad A Massy
Journal:  Nephrol Dial Transplant       Date:  2012-12-09       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.